Jan Endell

877 total citations
23 papers, 666 citations indexed

About

Jan Endell is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, Jan Endell has authored 23 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Genetics. Recurrent topics in Jan Endell's work include Chronic Lymphocytic Leukemia Research (8 papers), Multiple Myeloma Research and Treatments (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Jan Endell is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Multiple Myeloma Research and Treatments (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Jan Endell collaborates with scholars based in Germany, United States and Austria. Jan Endell's co-authors include Rainer Boxhammer, Michael Hallek, Hildegard Büning, Luca Perabò, Stefan Steidl, Susan King, David M. Kofler, Stefan Finke, Kristin Leike and Grzegorz S. Nowakowski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jan Endell

23 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Endell Germany	12	362	290	226	132	98	23	666
Michael J. Kadan United States	11	440 1.2×	357 1.2×	410 1.8×	74 0.6×	49 0.5×	16	828
Jiahua Qian United States	17	312 0.9×	351 1.2×	333 1.5×	366 2.8×	162 1.7×	31	1.1k
Babak Moghimi United States	14	493 1.4×	399 1.4×	474 2.1×	120 0.9×	46 0.5×	23	1.0k
Luisa Albano Italy	11	780 2.2×	341 1.2×	438 1.9×	71 0.5×	66 0.7×	22	1.1k
Charlotte Boix France	14	737 2.0×	187 0.6×	176 0.8×	33 0.3×	170 1.7×	16	1.0k
Dennis K. Watson United States	11	642 1.8×	136 0.5×	154 0.7×	86 0.7×	52 0.5×	18	878
Dalia Pinchasi Israel	8	648 1.8×	133 0.5×	136 0.6×	63 0.5×	88 0.9×	8	927
Hanna IJspeert Netherlands	20	530 1.5×	206 0.7×	162 0.7×	68 0.5×	129 1.3×	42	1.2k
Fraser McBlane United States	12	600 1.7×	121 0.4×	146 0.6×	77 0.6×	34 0.3×	17	852
Alar Aints Sweden	13	454 1.3×	222 0.8×	233 1.0×	133 1.0×	40 0.4×	23	952

Countries citing papers authored by Jan Endell

Since Specialization

Citations

This map shows the geographic impact of Jan Endell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Endell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Endell more than expected).

Fields of papers citing papers by Jan Endell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Endell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Endell. The network helps show where Jan Endell may publish in the future.

Co-authorship network of co-authors of Jan Endell

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Endell. A scholar is included among the top collaborators of Jan Endell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Endell. Jan Endell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Her, Jung Hyun, Yu Kyeong Hwang, Timm Hoeres, et al.. (2022). Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunology Immunotherapy. 71(11). 2829–2836. 9 indexed citations

Horvei, Paulina, Reona Sakemura, Michelle J. Cox, et al.. (2020). Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. Biology of Blood and Marrow Transplantation. 26(3). S223–S224. 7 indexed citations

Horvei, Paulina, Reona Sakemura, Michelle J. Cox, et al.. (2019). Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. Blood. 134(Supplement_1). 2859–2859. 9 indexed citations

Her, Jung Hyun, Sungyoo Cho, Yu Kyeong Hwang, et al.. (2019). Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208). Blood. 134(Supplement_1). 3801–3801. 1 indexed citations

Horna, Pedro, Grzegorz S. Nowakowski, Jan Endell, & Rainer Boxhammer. (2019). Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. Blood. 134(Supplement_1). 5345–5345. 35 indexed citations

Boxhammer, Rainer, Frank Striebel, Roland Baumgartner, & Jan Endell. (2019). Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data. Blood. 134(Supplement_1). 5061–5061. 8 indexed citations

Jurczak, Wojciech, Pier Luigi Zinzani, Gianluca Gaïdano, et al.. (2016). Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. Blood. 128(22). 623–623. 6 indexed citations

Raab, Marc S., Manik Chatterjee, Hartmut Goldschmidt, et al.. (2016). MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase I/IIa study.. Journal of Clinical Oncology. 34(15_suppl). 8012–8012. 16 indexed citations

Boxhammer, Rainer, Johannes Weirather, Stefan Steidl, & Jan Endell. (2015). MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds. Blood. 126(23). 3015–3015. 20 indexed citations

10.

Boxhammer, Rainer, Stefan Steidl, & Jan Endell. (2015). Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.. Journal of Clinical Oncology. 33(15_suppl). 8588–8588. 24 indexed citations

11.

Seidl, Christof, Birgit Blechert, Florian Gaertner, et al.. (2014). α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget. 6(7). 4692–4703. 38 indexed citations

12.

Endell, Jan, Rainer Boxhammer, & Stefan Steidl. (2014). Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide. Blood. 124(21). 5712–5712. 8 indexed citations

13.

Rommel, Christina E., Jan Endell, Petra Göring, et al.. (2012). Macroporous silicon chips for laterally resolved, multi-parametric analysis of epithelial barrier function. Lab on a Chip. 12(13). 2329–2329. 8 indexed citations

14.

Winderlich, Mark, Daniel Ness, Stefan Steidl, & Jan Endell. (2012). Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma.. Journal of Clinical Oncology. 30(15_suppl). 6574–6574. 3 indexed citations

15.

Endell, Jan, Rainer Boxhammer, Cornelia Wurzenberger, Daniel Ness, & Stefan Steidl. (2012). The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo. Blood. 120(21). 4018–4018. 31 indexed citations

16.

Endell, Jan, Christina Samuelsson, Rainer Boxhammer, Sandra J. Strauss, & Stefan Steidl. (2011). Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.. Journal of Clinical Oncology. 29(15_suppl). 8078–8078. 9 indexed citations

17.

Wolterink, Silke, Gerhard Moldenhauer, Mina Fogel, et al.. (2010). Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma. Cancer Research. 70(6). 2504–2515. 60 indexed citations

18.

Perabò, Luca, Kathryn White, Jan Endell, et al.. (2006). Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo Tropism. Journal of Virology. 80(14). 7265–7269. 104 indexed citations

19.

Perabò, Luca, et al.. (2005). Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus. The Journal of Gene Medicine. 8(2). 155–162. 106 indexed citations

20.

Perabò, Luca, Jan Endell, Kristin Leike, et al.. (2005). Green Fluorescent Protein-Tagged Adeno-Associated Virus Particles Allow the Study of Cytosolic and Nuclear Trafficking. Journal of Virology. 79(18). 11776–11787. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact